Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
StabiliMax is a high-viscosity bone cement primarily composed of polymethyl methacrylate (PMMA). It is developed and marketed as a medical device for use in orthopedic procedures, specifically vertebroplasty and kyphoplasty, to treat painful vertebral compression fractures (VCFs) resulting from osteoporosis, benign lesions, or malignant tumors. The material acts as a structural stabilizer by filling the void within the vertebral body, where it undergoes an exothermic polymerization reaction to harden and provide immediate internal fixation. This stabilization helps to alleviate pain and prevent further collapse of the vertebral structure. StabiliMax is designed with a high initial viscosity to provide controlled delivery and minimize the risk of cement leakage into surrounding tissues or the venous system during injection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on StabiliMax.